Objective: To investigate the efficacy and safety of ixazomib combined with thalidomide and dexamethasone in the treatment of multiple myeloma (MM).
Methods: The clinical data of 60 MM patients admitted to our center from January 2019 to June 2022 were analyzed retrospectively, including 43 newly diagnosed patients and 17 patients with recurrence and progression. All patients were treated with ixazomib combined with thalidomide and dexamethasone, and completed 2 to 7 treatment cycles.
Results: The overall response rate (ORR) of all patients was 98.3%. Among them, 53 patients completed 4 treatment cycles, and the ORR was 86.8%. Seventeen patients completed the whole treatment cycle, with curative effect reaching 88.2% achieving very good partial response and above, and 52.9% achieving complete response and above. Albumin and β2-microglobulin of all patients had been improved rapidly after treatment. The deadline was August 31, 2022. The median follow-up time was 14(3-24) months, and overall survival (OS) rate was 86.67%. The OS rate of patients with recurrence and progression was significantly lower than that of newly diagnosed patients (P < 0.05). The most common adverse reaction of hematology was lymphopenia (53.3%), followed by anemia (33.3%). The most common non-hematological adverse reaction was fatigue (68.33%), followed by peripheral neuropathy (31.67%).
Conclusion: Ixazomib combined with thalidomide and dexamethasone is effective in the treatment of MM, with good short-term efficacy, survival and safety. However, its long-term efficacy needs further observation.
题目: 伊沙佐米联合沙利度胺和地塞米松治疗多发性骨髓瘤的疗效及安全性评价.
目的: 探讨伊沙佐米联合沙利度胺和地塞米松治疗多发性骨髓瘤的疗效及安全性。.
方法: 回顾性分析本中心2019年1月至2022年6月收治的60例多发性骨髓瘤患者的临床资料,其中初诊患者43例,复发进展患者17例。全部患者使用伊沙佐米联合沙利度胺和地塞米松治疗,均完成2-7个治疗周期。.
结果: 全部患者总缓解率为98.3%,其中完成4个治疗周期的患者共有53例,总缓解率为86.8%。完成全部治疗周期的患者有17例,疗效达到非常好的部分缓解及以上占88.2%,完全缓解及以上占52.9%。全部患者经治疗后白蛋白、β2-微球蛋白的水平得到迅速改善。随访截止时间为2022年8月31日,中位随访时间为14(3-24)个月,总生存率为86.7%。复发进展患者的总生存率显著低于初诊患者(P < 0.05)。最常见的血液学不良反应为淋巴细胞降低(53.3%),其次为贫血(33.3%);最常见的非血液学不良反应为乏力(68.33%),其次为周围神经病变(31.67%)。.
结论: 伊沙佐米联合沙利度胺和地塞米松治疗多发性骨髓瘤的疗效确切,近期疗效、生存情况、安全性良好,但远期疗效还需要进一步观察。.
Keywords: multiple myeloma; ixazomib; thalidomide; dexamethasone; efficacy.